Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL656955 | 0.90 | MAPT (0.52) | MAPTALDH1A1MAOBKMT2AMEN1 | |
| SCHEMBL656975 | 0.84 | MAPT (0.40) | MAPTALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL7885636 | 0.81 | MAPT (0.47) | MAPTMAOBKMT2AMEN1MAOA | |
| SCHEMBL7885792 | 0.81 | TBXA2R (0.47) | MAPTALDH1A1LMNAMAOBKMT2A | |
| SCHEMBL8417803 | 0.80 | LMNA (0.52) | MAPTALDH1A1LMNAKCNH2PTGS2 | |
| SCHEMBL16388043 | 0.77 | HSP90AA1 (0.51) | MAPTALDH1A1LMNA | |
| Potassium Ion SCHEMBL657320 | 0.77 | HSP90AA1 (0.50) | MAPTALDH1A1LMNA | |
| SCHEMBL656312 | 0.76 | MAOB (0.55) | MAPTLMNAMAOBKMT2AMEN1 | |
| SCHEMBL657376 | 0.75 | CYP3A4 (0.51) | MAPTMAOBKMT2AMEN1POLB | |
| SCHEMBL3715889 | 0.75 | HSP90AA1 (0.47) | MAPTALDH1A1LMNAKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993556-B2 | Resorcinol derivatives as HSP90 inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-03-31 | — | — | US | disclosed |
| EP-2421833-B1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-01-14 | — | — | EP | disclosed |
| EP-2421833-B1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-01-14 | — | — | EP | disclosed |
| EP-2421833-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2012-02-29 | — | — | EP | disclosed |
| US-20120046266-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-23 | — | — | US | disclosed |
| WO-2010121963-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046266-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90AB2P | MAPT 84/4885ALDH1A1 1996/4885LMNA 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.